Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group
Abstract
This addendum to our previous Comment provides additional guidance from the European ADHD Guidelines Group (EAGG) on starting attention-deficit hyperactivity disorder (ADHD) medications (specifically psychostimulants and atomoxetine), during the coronavirus disease 2019 (COVID-19) pandemic, for patients who did not have a baseline, face-to-face cardiovascular assessment before the crisis began.
Author
Citations
Altmetric:
Date
2020
Type
Correspondence
Subject
Pandemics, Attention deficit disorder with hyperactivity, COVID-19, SARS-CoV-2
Collections
Citation
Cortese, S., Coghill, D., Santosh, P., Hollis, C. P. & Simonoff, E. (2020). Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. The Lancet Child & Adolescent Health, 4 (June), pp.e15.